EcoVadis Silver Medal! PharmaBlock Excels in Sustainability

PharmaBlock Group has been awarded a Silver Medal for sustainability by EcoVadis, ranking us in the top 15% globally!

PharmaBlock Sciences (Nanjing), Inc. (stock code: 300725.SZSE) is thrilled to announce that its Nanjing Headquarters and R&D Center has been awarded a Silver Medal for the sustainability performance with EcoVadis, a global leader in business sustainability assessments. This prestigious recognition positions PharmaBlock in the top 15% of companies assessed worldwide, surpassing tens of thousands of participants in the global evaluation. Moreover, the company’s manufacturing sites in Zhejiang and Shandong have each earned Bronze Medals, further underscoring PharmaBlock Sciences’ dedication to sustainable excellence.

EcoVadis is a globally trusted provider of business sustainability ratings with a network of more than 130,000 rated companies. Its comprehensive evaluations encompass critical domains including Environment, Labor and Human Rights, Ethics, and Sustainable Procurement, offering organizations detailed analyses and strategies for sustainability improvement. These assessments Their assessments cover crucial areas like Environment, Labor and Human Rights, Ethics, and Sustainable Procurement, offering organizations detailed analyses and strategies for sustainability improvement. These evaluations are pivotal in bolstering a company's international reputation and competitive positioning.

“Sustainable development is at the heart of our corporate strategy,” said Dr. Minmin Yang, Founder of PharmaBlock Sciences. “Our exceptional performance in EcoVadis’ recent evaluation addresses our unwavering commitment to ESG excellence. This accolade not only signifies the company’s substantial strides in ESG performance but also affirms our position at the forefront of global pharmaceutical R&D and manufacturing.”

PharmaBlock is honored to have its efforts in ESG and sustainability recognized. In August 2024, the company's Wind ESG rating was elevated to "AA". Furthermore, in September, PharmaBlock was named as a finalist for the CPHI Pharma Awards 2024 in the Sustainability category. This nomination follows the company’s receipt of the CPHI China ESG Sustainability Influencer Award in June, marking another opportunity to secure a prestigious industry sustainability honor.

In recent years, PharmaBlock Sciences has actively participated in the United Nations Global Compact (UNGC) and submitted it application to the Science Based Targets initiative (SBTi), affirming its steadfast commitment to global sustainable development goals. The company has proactively aligned its management systems with international ESG standards, expanding its certification portfolio beyond ISO 9001 Quality Management, ISO 14001 Environmental Management, and ISO 45001 Occupational Health and Safety Management to include ISO 50001 Energy Management, ISO/IEC 27001 Information Security Management, and GB/T 39604-2020 Social Accountability (SA) Management. These accreditations signify PharmaBlock’s substantial progress in energy efficiency, lean operations, and social responsibility governance, emphasizing the company’s pursuit of excellence in sustainability and operational performance.

PharmaBlock Sciences is dedicated to its mission of "We innovate Chemistry for a Greener and Healthier World," striving to drive sustainable development within the industry through innovative advancements in chemistry and low-carbon technologies. Leveraging state-of-the-art techniques such as continuous flow processes and micro-packed hydrogenation, the company has received the ACS CMO Excellence in Green Chemistry Award for two consecutive years in 2023 and 2024. This recognition underscores PharmaBlock's commitment to providing clients with more efficient, environmentally friendly, and safer drug development and manufacturing services, but also sets a benchmark for driving the industry's green transformation.

In future, PharmaBlock will intensify its ESG efforts by prioritizing customer needs and driving growth through pioneering innovations in chemistry and low-carbon technologies. In unity with industry partners, the company is steadfast in its commitment to enhancing the efficiency of pharmaceutical research and development, collectively steering the industry toward a greener and more sustainable future.